logo Hematology/Oncology Research Studies: Open for Enrollment Date: 01/23/20


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

NCT#/Phase: NCT03213652
Phase 2
IRB#: 2017-095f
Description: This is a subprotocol of the MATCH trial APEC1621 and is a phase 2 trial of ensartinib in children with recurrent or refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses and CNS involvement) harboring specified activating genetic alterations in ALK or ROS1 pathway genes. This study aims to determine the objective response rate of Ensartinib, a second-generation oral ALK inhibitor that also has activity against a panel of kinases including ROS1, c-met, trkA, and axl.
Inclusion: Individuals who are between 12 months and 21 years of age and given a therapy assignment to MATCH to APEC1621F.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group (COG)
Principal Investigator(s): Carla Golden, MD
Contact(s): Diane Olszewski (510-428-3885 x 3246)
COG CRA Office (510-428-3885 x8334)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03213652

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000